ArticleRenal failure2025
Renal survival and improvement in younger malignant hypertension patients with thrombotic microangiopathy.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension (HTN) is increasing among young people. Notably, younger individuals are more susceptible to malignant hypertension (MHT). The occurrence and renal prognosis in MHT patients with thrombotic microangiopathy (TMA) across different age groups remains undetermined. This prospective cohort study evaluated 292 MHT patients with TMA in China from 2008 to 2023. We examined the clinical and pathological characteristics according to median age categories (≤35 years and >35 years). The associations of age with renal outcomes were examined in Cox regression models. The primary outcome was long-term renal replacement therapy (RRT). The secondary outcome was an increase of at least 15% in estimated glomerular filtration rate (eGFR). Among 292 patients, individuals younger than 35 years had significantly higher proteinuria, proportion of patients with immunoglobulin A nephropathy (IgAN), and global sclerosis ratio compared to those older than 35 years. Age ≤35 years was associated with a worse outcome of long-term RRT outcome (Hazard ratios [HRs]: 1.60 [95% confidence interval [CI]: 1.06-2.40]) and better improvement of ≥15% increase in eGFR (HRs: 1.93 [95% CI: 1.20-3.11]). Serum creatinine >565 μmol/L and proteinuria >1.41 g/d were associated with a higher risk of long-term RRT, while serum albumin >35 g/L was correlated with a lower risk of it. Tubular atrophy/interstitial fibrosis >50% was an unfavorable factor for ≥15% increase in eGFR. In conclusion, young age contributed to a better renal improvement of ≥15% increase in eGFR, especially within 6 years. However, a worse outcome of long-term RRT also occurred in the younger MHT patients with TMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.